Huaxia Health (hk 1 143): 201710 12, Huaxia Health (HK1143
This time, the cooperation between Tianke Health Choice and China Health not only means that the enterprise has officially entered the capital market and become the first port of polyurethane condoms in China, but also brings great development opportunities for its brand Zhongchuan 00 1 and opens up channels for it to enter the international market. For Huaxia Health, this big deal also reflects the firm optimism about the brand, technology and market prospects of Zhongchuan 00 1. According to market analysis, Huaxia Health 4. In the next two years, it will be HK$ 6543.8+300 million, with a profit of nearly HK$ 700 million.
From August 28th, 20 16, the first domestic water-borne polyurethane condom production line was completed and put into production, and by the end of 20 17, five production lines were put into production in an all-round way, and the production capacity broke out in an all-round way. Excellent technical support and rapid brand growth have made Zhongchuan 00 1 highly concerned and favored by the capital market. It is understood that Landa Tianke Health is the first enterprise in China to obtain the production license and sales license of polyurethane condoms, and it is also the only enterprise in the world to master the dual technology of waterborne polyurethane resin and waterborne polyurethane condoms. The healthy listing of Tianke will put the brand of Zhongchuan 00 1 in a global perspective, which will not only bring a good experience to foreign consumers, but also bring the development of enterprises to a new height.
Renfu Medicine (600079): Renfu Medicine announced that it plans to invest $600 million with CITIC Capital * * * to acquire Ansel's global health business, including Jasper. After the acquisition, Renfu Medicine will become the global leader in gender health and the second largest enterprise in the global condom market. Previously, Jasper was sold by Renfu Medicine twice. Eleven years later, Renfu Medicine announced its intention to acquire Carlsberg. Jasper was incorporated in Wuhan on February 1 2006. After five years of operation, it was reviewed and approved by the board of directors of Renfu Medicine on February 13, 2006. 70% of the shares of Jasper were sold to Jasper PDIPL and Deng Lupu for 3.7 billion yuan.